AI Article Synopsis
Article Abstract
Introduction: Legislatures across the country are passing new opioid prescribing laws. To understand the effects of this legislation, baseline autonomous shifts in physician opioid prescribing must be evaluated.
Methods: The purpose of this retrospective dual cohort comparison study was to evaluate 5-year opioid prescribing trends in orthopaedic trauma patients. Demographic and injury information were collected on adult trauma patients with surgically managed orthopaedic fractures from 2012 (N = 190) and 2017 (N = 160). The amount of opioid medication prescribed from discharge to 1 year after the injury was collected. Opioid prescriptions were converted to morphine milligram equivalents (MMEs). The main outcome measure was opioid medication prescribed in 2017 versus 2012.
Results: The cohorts were well-matched on sex, race, medical comorbidities, substance use, fracture location, Injury Severity Score, hospital length of stay, and intensive care unit admission metrics. However, the 2012 cohort was older than the 2017 cohort (51.9 versus 43.3 years, P < 0.001). When controlling for age, total opioid medication prescribed was greater in 2012 than in 2017 (1,680 versus 1,110 MME, P = 0.001). Patients in 2017 received both lower discharge prescriptions (523 versus 407 MME, P < 0.001) and lower total opioid prescription refill amounts (1,140 versus 766 MME, P = 0.037). The number of refills prescribed was equal, but patients received lower amounts of opioid medications per refill in 2017 (333 versus 243 MME, P < 0.001). Despite these differences, the percentage of patients ceasing prescription opioid use 1 year after injury was unchanged (90.6% versus 92.1%, P = 0.675).
Discussion: Over 5 years, providers have successfully reduced the amount of opioid medication prescribed to surgically managed orthopaedic trauma patients through self-directed measures. The effects of opioid prescribing legislation should be viewed from this baseline.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447465 | PMC |
| http://dx.doi.org/10.5435/JAAOSGlobal-D-20-00134 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Do we need urine drug screens in opioid addiction treatment: An observational study on self-report versus urine drug screens.
Addict Behav Rep
June 2025
Department of Psychiatry and Behavioural Neurosciences, McMaster University, 100 West 5th St., Hamilton, ON L8N 3K7, Canada.
Background: The substance use crisis continues to progress. Medication for Opioid Use Disorder (MOUD) are prescribed to reduce opioid use and related harms; however, many individuals continue to use substances while on treatment. The objective of this study was to describe the temporal and demographic trends of the agreement between self-reported and urine tested substances.
View Article and Find Full Text PDFTrends in naloxone co-prescriptions.
Drug Alcohol Depend
December 2024
Stanford University School of Medicine, Office of PA Education, 300 Pasteur Drive, Stanford, CA, United States; Stanford University School of Medicine, Department of Medicine, Division of Primary Care and Population Health, 300 Pasteur Drive, Stanford, CA, United States; Kaiser Permanente Mountain View Medical Offices, Department of Internal Medicine, 555 Castro Street, Mountain View, CA, United States. Electronic address:
Background: The opioid epidemic remains a significant public health crisis in the United States. Naloxone has been identified as a critical component in combating this crisis. However, co-prescription rates among patients receiving opioids remain suboptimal, especially among certain high-risk populations.
View Article and Find Full Text PDFModulation of oxidative stress/NMDA/nitric oxide pathway by topiramate attenuates morphine dependence in mice.
Heliyon
December 2024
Department of Biomedical Sciences, Pak Austria Fachhochschule: Institute of Applied Sciences and Technology, Haripur, Khyber Pakhtunkhwa, Pakistan.
Morphine belongs to the class of opioids and is known for its potential to cause dependence and addiction, particularly with prolonged use. Due to the associated risks, caution must be taken when prescribing and limiting its clinical use. Overexpression of N-methyl-D-aspartate (NMDA) receptors, nitric oxide and cGMP pathway has been implicated in exacerbate the development of morphine dependence and withdrawal.
View Article and Find Full Text PDFOpioid prescribing prevalence and initiation rates in Victoria, Australia: insights from primary care data during a period of opioid policy changes (2017-2022).
Int J Clin Pharm
December 2024
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Level 2 Building D, 47-49 Moorooduc Highway, Frankston, Melbourne, VIC, 3199, Australia.
Background: Opioid medications are widely prescribed for acute, chronic and cancer pain. In Australia, opioid prescribing rates remain high.
Aim: This study aimed to document patterns of primary care opioid prescribing from 2017 to 2022 by demographic characteristics in Victoria, Australia.
Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive Genotyping in Cancer Palliative Care.
J Pain Res
December 2024
Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL, USA.
Background: Cancer patients frequently suffer from pain, often managed with opioids. However, undertreated pain remains a significant concern. Opioid effectiveness varies due to genetic differences in how individuals metabolize some of these medications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!